Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Recurrence × ridaforolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2 Solid Tumors 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphoma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Cancers 1

Interventions

Cyclophosphamide 32 Dexamethasone 30 Rituximab 22 Cytarabine 21 fludarabine phosphate 20 Methotrexate 17 Lenalidomide 17 fludarabine 15 Bortezomib 15 Peripheral Blood Stem Cell Transplantation 14 Calcium Dobesilate 14 Whole-Body Irradiation 13 Mycophenolic Acid 13 Etoposide 13 pembrolizumab 12 Melphalan 12 Filgrastim 12 Paclitaxel 11 Gemcitabine 11 Cyclosporine 11 Carboplatin 11 pomalidomide 10 Busulfan 10 Vincristine 9 carfilzomib 8 Tacrolimus 8 Panobinostat 8 Clofarabine 8 Cetuximab 8 Brentuximab Vedotin 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01380184 2019-04-19

MK-8669-059

Merck Sharp & Dohme LLC

Phase 1 Completed

15 enrolled 15 charts

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡